For professional laboratory research only
CJC-1295 (No DAC) + Ipamorelin Blend
An investigational blend of CJC-1295 No DAC and ipamorelin for investigation of GHRH and GHSR signalling. Available in vial format (5+5 MG). For laboratory research only.
Includes 1 × Bacwater 3 ml per vial
Documentation
Report available
Price per item
€ 74,95 incl. VAT
Free shipping on orders over €100.
Shipping and returns · Available delivery options are shown at checkout.
About CJC-1295 (No DAC) + Ipamorelin Blend
This format is offered as a research vial, with 5+5 MG as the stated strength. The product name, the selected format and the batch documentation together form the basis for comparing research materials. A stated quantity is not advice for use or dosage.
What is CJC-1295 (No DAC) + Ipamorelin Blend?
This blend combines the peptide presented as CJC-1295 No DAC with ipamorelin. The components are investigated in relation to different routes of growth hormone release.
The addition No DAC is essential when comparing literature. Research into long-acting, albumin-binding CJC-1295 does not directly support this No DAC blend.
What does the research focus on?
The area of research includes pituitary signalling and the comparison of different receptor-dependent pathways. A combination must be assessed as its own research material.
- GHRH-related signalling and the pathway by which ipamorelin is investigated.
- Separate and combined responses in an appropriate research model.
- Checking peptide identity, DAC status and component ratio.
Research references
The CJC-1295 article discusses an albumin binding analog and is not proof of this No DAC implementation. The sources also do not certify the combined Novogin blend.
For laboratory and analytical research only. Not for use in humans or animals, consumption, cosmetic use or use as a food supplement. This research material is not offered as an approved medicine. No medical, dosing or injection advice is provided.
Product specifications
| Product | CJC-1295 (No DAC) + Ipamorelin Blend |
|---|---|
| Format | Research vial |
| Stated strength | 5+5 MG |
| Research area | Growth hormone research |
| Storage | According to the current batch documentation |
| Intended use | Laboratory and analytical research |
Use in research
Use this material only as an experimental reagent within a documented laboratory or analytical protocol. Select the test method, model and working conditions using validated literature and product-specific technical documentation.
- Check the selected strength and batch identity before starting the experiment.
- Consult the current safety data sheet, certificate details and storage instructions.
- Validate solvent compatibility, concentration, stability and controls for the selected model.
- Document preparation, storage, handling and disposal within the laboratory workflow.
The product name alone does not establish a universal reconstitution or working protocol.
| Strength | 5+5 MG |
|---|---|
| COA status | Available |
Frequently asked questions
Is this the same blend as Tesamorelin + Ipamorelin?
No. The first component is CJC-1295 No DAC and not tesamorelin. The description and specifications of a tesamorelin blend are therefore not interchangeable.
What does the 5+5 MG designation mean?
The catalogue lists two component quantities. The available vial report #211784 reports measured content per component and does not provide a purity percentage for the blend.
What does the stated strength mean?
The catalogue mentions 5+5 MG. This designation describes the format offered and is not a concentration or recommended amount for an experiment. A measurement result from a report may deviate from the nominal label.
How should I store this product?
Follow the current storage information for the supplied batch and product format. Do not use a general storage temperature or shelf life from a comparable product as a substitute for its own documentation.
Batch & documentation
| Report number | 211784 |
|---|---|
| Laboratory | Janoshik |
| Analysis date | 2026-07-31 |
| Sample label | 5 mg + 5 mg |
| Format | Vial |
| Measured content | CJC-1295 No DAC: 4.75 mg; Ipamorelin: 4.27 mg |
| Documentation coverage | Linked products of the same substance, including their strength variants |
| Stock link for sampled variant | Current stock not confirmed |
| Documentation batch | 2608028 |
Measurements describe the tested sample. Documentation coverage does not automatically confirm the sale contents, device characteristics or supplied batch of every format. Check these separately.
